Department of Endocrinology "D. Ikkos", Diabetes Center, Evangelismos General Hospital, 10676 Athens, Greece.
Independent Researcher, 18535 Athens, Greece.
Medicina (Kaunas). 2024 Jul 30;60(8):1241. doi: 10.3390/medicina60081241.
Cardiovascular comorbidities owing to hormonal excess or deficiency are the main cause of mortality in patients with pituitary disorders. In patients with Cushing's Disease, there is an increased prevalence of cardiovascular diseases and/or risk factors including visceral obesity, insulin resistance, atherosclerosis, arterial hypertension, dyslipidaemia, hypercoagulability as well as structural and functional changes in the heart, like cardiac hypertrophy and left ventricle (LV) dysfunction. Notably, these demonstrate limited reversibility even after remission. Furthermore, patients with acromegaly may manifest insulin resistance but also structural and functional heart changes, also known as "acromegalic cardiomyopathy". Patients with prolactinomas demonstrate an aggravation of metabolic parameters, obesity, dysregulation of glucose and lipid metabolism as well as endothelial dysfunction. Hypopituitarism and conventional hormonal replacement therapy may also contribute to an unhealthy metabolic status, which promotes atherosclerosis and may lead to premature mortality. This review discusses the literature on cardiovascular risk in patients with pituitary disorders to increase physician awareness regarding this aspect of management in patients with pituitary disorders.
由于激素过多或不足引起的心血管合并症是垂体疾病患者死亡的主要原因。在库欣病患者中,心血管疾病和/或风险因素的患病率增加,包括内脏肥胖、胰岛素抵抗、动脉粥样硬化、动脉高血压、血脂异常、血液高凝状态以及心脏的结构和功能改变,如心肌肥厚和左心室(LV)功能障碍。值得注意的是,即使在缓解后,这些改变的可逆性也有限。此外,肢端肥大症患者可能表现出胰岛素抵抗,还会出现结构性和功能性心脏改变,也称为“肢端肥大性心肌病”。催乳素瘤患者表现出代谢参数恶化、肥胖、葡萄糖和脂质代谢失调以及内皮功能障碍。垂体功能减退症和常规激素替代疗法也可能导致不健康的代谢状态,促进动脉粥样硬化,并可能导致过早死亡。这篇综述讨论了关于垂体疾病患者心血管风险的文献,以提高医生对垂体疾病患者管理这一方面的认识。